Purpose: Electrographic seizures are common in encephalopathic critically ill children, but identification requires continuous EEG monitoring (CEEG). Development of a seizure prediction model would enable more efficient use of limited CEEG resources. We aimed to develop and validate a seizure prediction model for use among encephalopathic critically ill children. Method: We developed a seizure prediction model using a retrospectively acquired multi-center database of children with acute encephalopathy without an epilepsy diagnosis, who underwent clinically indicated CEEG. We performed model validation using a separate prospectively acquired single center database. Predictor variables were chosen to be readily available to clinicians prior to the onset of CEEG and included: age, etiology category, clinical seizures prior to CEEG, initial EEG background category, and inter-ictal discharge category. Results: The model has fair to good discrimination ability and overall performance. At the optimal cut-off point in the validation dataset, the model has a sensitivity of 59% and a specificity of 81%. Varied cut-off points could be chosen to optimize sensitivity or specificity depending on available CEEG resources.
Introduction
Electrographic seizures (ES) are reported in 10-50% of children with acute encephalopathy who undergo continuous EEG monitoring (CEEG), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and there is increasing evidence that high ES burdens are associated with worse outcomes, even in models that adjust for acute encephalopathy etiology and severity. 10, 13, 17, 20, 21 Most ES in critically ill children have no clinical correlate so CEEG is required for identification, 3, 6, [8] [9] [10] [12] [13] [14] [15] 18, 19 leading to recent increases in CEEG use within pediatric intensive care units (PICUs). 22 CEEG is resource intense, and seemingly small changes in CEEG utilization may have substantial impacts on equipment and personnel needs. 23 Seizure prediction models could allow CEEG to be targeted to children at highest risk for experiencing ES within the resource limitations of an individual medical center. Several studies have described clinical and EEG risk factors for ES. However, these data are limited in several ways. First, the data are obtained from patients who have undergone CEEG at single or few institutions, 3, [7] [8] [9] 11, 12, 14, 17, 18 so the risk factors identified may not be useful if implemented at a different institution with different patient characteristics or CEEG practice. Although multicenter consortia are starting to study ES epidemiology, 13, 24, 25 multi-center data variability might preclude meaningful application at individual centers. Second, prior studies have not combined the identified risk factors to create clinically useful ES prediction models accounting for multiple risk factors. Currently, a clinician may consider multiple known seizure risk factors (such as younger age, prior convulsive seizures, and inter-ictal epileptiform discharges) when making a clinical judgment regarding the need for CEEG, but there are no data available to help determine the accuracy of this combinatorial approach. We aimed to determine whether an ES prediction model developed from retrospective multi-center data could be used to predict ES occurrence when applied to data obtained from a single center.
Methods

Datasets
The model was created and validated using separate datasets of children in PICUs who underwent clinically indicated CEEG. The overall study was approved by The Children's Hospital of Philadelphia institutional review board, and submission of data was approved by the institutional review boards at each site.
The model creation dataset was derived from a multi-center study in which 11 sites each collected data by retrospective chart review on 50 consecutive critically ill children to yield 550 subjects. 13, 24, 25 The 11 sites were large academic medical centers with available pediatric neurology consultation and CEEG. Subjects had undergone clinically indicated CEEG as dictated by practice patterns at each institution and not any study protocol or national guideline. Thus, these subjects were heterogeneous in terms of etiology, degree of encephalopathy, and other clinical characteristics. For the current study, we excluded 214 subjects with pre-existing epilepsy-related diagnoses leading to PICU admission, leading to a cohort of 336 subjects. Patients with epilepsy were excluded for several reasons. Prior classification proposals have differentiated between non-convulsive status epilepticus (NCSE) as occurring in the context of acute brain injury (termed ''comatose NCSE'') and occurring in the context of more benign epilepsy conditions (termed ''NCSE proper'') since the relative impact of seizures to overall prognosis differs. 26 Our aim was to address the use of CEEG when screening for electrographic seizures in patients with acute encephalopathy in whom seizure identification and management might serve as a neuroprotective strategy. Second and more practically, institutional practice, bed availability, and admission time of day likely impact decisions regarding whether patients with epilepsy in need of CEEG are admitted to the epilepsy monitoring unit or PICU. Data were obtained by chart review from the reports created by trained encephalographers on-service when the CEEG was obtained and the tracings were not re-interpreted for this study. The model validation dataset was derived from a prospective single center dataset from The Children's Hospital of Philadelphia and included 222 subjects who underwent CEEG while in the PICU without an epilepsy-related diagnosis prior to admission. As described above, patients with epilepsy were excluded. Institutional practice at The Children's Hospital of Philadelphia is to obtain at least one day of CEEG in any patient admitted to the PICU with encephalopathy of any degree and any acute neurologic condition (i.e. traumatic brain injury, stroke, hypoxic ischemic encephalopathy, encephalitis). These were different subjects than those contributed by The Children's Hospital of Philadelphia to the multi-center model creation dataset. Epidemiologic data from a portion of this dataset have been published previously. 18 The single center validation data were obtained prospectively by one investigator (N.S.A.) who re-scored the CEEG after clinical interpretation for seizure category and background category while blind to clinical data other than age. We categorized subjects by ES category (none, electrographic seizures, electrographic status epilepticus). Electrographic status epilepticus was defined as a single or recurrent electrographic seizure(s) lasting 30 min or more within a 1 hour epoch. We collected data regarding clinical variables previously identified as predicting an increased risk of experiencing ES. Age was classified as >24 months or 24 months. Clinically evident seizures prior to CEEG were classified as present or absent. Etiology category was classified as structural (i.e. traumatic brain injury, stroke (ischemic or hemorrhagic), hypoxic-ischemic encephalopathy, encephalitis, posterior reversible leukoencephalopathy) or non-structural (hepatic encephalopathy, sepsis, metabolic disorders). The initial 1 h EEG background categorization (normal/sleep, slow-disorganized, discontinuous, burst-suppression, or attenuated/featureless), and initial one hour EEG inter-ictal epileptiform discharge (IED) categorization (present or absent). This background categorization scheme has been used in prior studies related to EEG in critically ill children. 13, 20, 21 When EEGs from critically ill children are reviewed by pediatric encephalographers, inter-rater agreement for background features continuity (continuous, discontinuous, flat) and 
, to let it range between 0% and 100% to ease the interpretation. Accurate predictions discriminate between subjects with and without ES. The concordance statistic (c-statistic) was used to indicate the discriminative ability of the logistic regression model. The c-statistic represents the probability that a subject who experiences an ES has a higher predicted probability than a seizure absent subject for a random pair of subjects consisting of one subject with and one subject without an ES. It is equivalent to the area under the receiver operating characteristic (ROC) curve (AUC) for binary outcomes. 29 Higher values were considered to demonstrate better discrimination abilities as follows: excellent (AUC ! 0.90), good (0.80 AUC < 0.90), fair (0.70 AUC < 0.80), and poor (AUC < 0.70). 30 In addition, the discrimination slope was used to measure how well subjects with and without ES were separated. It was calculated as the absolute difference in average predictions for subjects with and without ES. The validity of the predicted SE was measured graphically by plotting the predicted outcomes on the x-axis and the observed outcomes on the y-axis. This calibration plot assesses the agreement between the observed outcomes and predicted outcomes. A 45-degree line would represent perfect prediction. Since the outcomes in the study were binary with only 0 or 1 value for the y-axis, we plotted observed outcome by decile of predictions and added smoothing line by LOESS (locally estimated scatterplot smoothing). The closeness of the smoothing line and the 45-degree line is a visualization of the agreement/calibration. 31 The performance for calibration was measured using a recalibration model logit(y) = a + b Â linear predictors proposed by Cox.
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The values for a and b are two indicators for calibration performance. For regression model development, a = 0 and b = 1 were set as fixed. For validation, a departure from zero for intercept a indicated that the predictions were systematically too low or too high given that b set to 1. A value of calibration slope b smaller than 1 given that a set to 0 reflected over-fitting of the model, indicating that the predictions are too extreme (overly low estimates for low predictions and overly high estimates for high predictions). The observed outcome by decile of prediction in this calibration plot is equivalent to a graphical illustration of the Hosmer-Lemeshow test, 33 which was used to test agreement between the observed frequencies and predicted probabilities. A high Hosmer-Lemeshow statistic is related to a small p-value and indicates lack of fit. Jack-knife cross-validation was used on the creation dataset as a measure of internal validation to obtain an overall prediction error. The model was then applied to the external dataset to test its performance using all the measures above.
The predicted ES probabilities were calculated from the model, and they were termed model scores. Sensitivity and specificity were obtained from various model score cut-offs, assuming patients receiving model scores above the cut-off would be selected to undergo CEEG. Positive predictive values (PPV) and negative predictive values (NPV) were calculated using a 30% ES prevalence based on multi-center seizure prevalence data. 13 Table 1 provides summary characteristics regarding the clinical and EEG variables from the model creation and model validation datasets. The two datasets were similar in the percentages of males, subjects younger than two years, occurrence of clinically evident seizures prior to CEEG, and typical background EEG category. The model creation dataset contained a higher proportion of subjects with IEDs and the model validation dataset contained a higher proportion of subjects with ES and with structural neurologic diagnoses.
Results
Descriptive statistics
Model creation dataset
The best model for discriminating between ES category outcomes was identified using logistic regression. All variables used in the univariate analysis remained significant in the multivariate analysis except for Etiology Category (Wald z = À1.47, p = 0.1423), which was removed from the final model. Table 2 provides the beta-coefficients and odds ratios from this model. The strongest predictor of ES presence was EEG background; seizures were more likely in subjects with burstsuppression and attenuated/featureless backgrounds. Other variables associated with higher odds of ES occurrence were: age 24 months, clinically evident seizures prior to CEEG, and the presence of IEDs. Table 3 provides the final regression formula as well as the calculated risk values (model scores) for each possible combination of variables. Supplemental Fig. 1 provides a graphical summary of the model scores.
A model with good discrimination will show a wide spread in the distribution of the predicted probabilities away from the average probability. Fig. 1 shows the distribution of the probabilities for subjects per outcome value (seizures absent or present). Subjects who experienced ES had 27% higher predicted ES probabilities than subjects who did not experience ES. The c-statistic/area under the curve was 0.845 ( Fig. 1) indicating the model had good discrimination ability in the model creation dataset. Table 4 provides the sensitivities and specificities using different model scores cut-offs. In practice, patients with model scores above the cut-off would be considered at higher risk for experiencing ES and would undergo CEEG. A model score cut-off of 0.2 maximized sensitivity and specificity in the creation model. The model worked well in the creation dataset with a Brier score of 0.121 indicating an informative prediction. The Hosmer-Lemeshow goodness-of-fit test was not significant (x 2 = 6.01, pvalue = 0.65) indicating the model had adequate fit for this dataset.
In the model creation dataset, the prediction error from jack-knife cross-validation was 13%, suggesting that approximately 87% of the cases would be correctly classified.
Model validation dataset
Overall model performance in the model validation dataset was less than in the creation dataset, according to R 2 (35% for validation dataset in contrast to 37% for creation dataset) and Brier score (0.23 for validation dataset in contrast to 0.12 for creation dataset). The c-statistic AUC was 0.799, indicating fair discrimination ability in the model validation dataset. The discrimination slope was 0.16 ( Fig. 1) indicating on average the difference in the predicted probability between the two outcome groups was 16%. Fig. 1 provides the calibration plots of the model predicting ES presence for the model validation dataset. The intercept and slope of the calibration line were estimated in a logistic regression model with the linear predictor w calculated for the patients of the validation dataset, as the only predictor variable: log odds = a + b linear predictor. The calibration intercept was 1.42 which is greater than zero indicating the predicted probabilities were systematically too low. The slope was 0.96 which is close to 1 and therefore indicates that the model is not too optimistic (over-fitting). This type of miscalibration (slope close to 1 and the intercept different from 0) indicates that certain patient characteristics not included in the prediction model were differently distributed in the validation sample compared with the model creation sample. The Hosmer-Lemeshow test was statistically significant (x 2 = 104, p-value < 0.0001) indicating a lack of fit in the model validation dataset, which agrees with the calibration plot. The sensitivities and specificities using different model score cut-offs are shown in Table 4 . Using the optimal 0.2 model score cut-off identified in the model creation dataset, only 25% of patients in the model validation dataset who might have undergone clinically indicated CEEG would be selected to undergo CEEG. This practice would lead to lower resource requirements but would fail to identify some patients experiencing ES.
Discussion
A seizure prediction model derived from a retrospectively acquired multi-center dataset provides useful ES predictions when validated using a single center dataset. Having a model that discriminates well between patients who will and will not experience ES can improve resource utilization since limited CEEG resources can be directed to the patients most at risk for experiencing ES. While imperfect, our model has a fair to good discrimination even on the validation dataset indicating that most patients could be appropriately classified.
Many studies have indicated that 10-50% of children with acute encephalopathy who undergo CEEG experience ES. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Because CEEG is resource intense and a limited number of patients might be able to undergo CEEG at a given center, using this model derived from a small number of clinically evident risk factors might improve CEEG efficiency. This model could be applied clinically in a few steps. First, the clinician must know several clinical variables and EEG variables which could be obtained from a routine EEG. Second, using these variables, the clinician can calculate the model score using the logistic regression formula or, more easily, by locating the appropriate row in Table 3 or location on Supplemental Fig. 1 , both of which provide pre-calculated model scores for each combination of variables. Third, patients with model scores above the institutional cut-off would be selected to undergo CEEG. Individual institutions might pick different model score cut-offs based on center-specific criteria. A model score cut-off of 0.20 had the best overall test characteristics. Given a seizure prevalence of 30%, the estimated PPV was 57% and NPV was 82%. Only 25% of patients who might have undergone clinically indicated CEEG would be classified as needing CEEG, leading to lower resource requirements. However, 41% of patients experiencing ES would not be classified as needing CEEG and thus the ES would not be identified. A center with substantial CEEG resources might perform CEEG for any patient with a model score >0.10. At this cut-off, 14% of patients with ES would not undergo CEEG so the seizures would not be identified and managed. However, 58% of patients without ES would be identified as not needing CEEG, so limited CEEG resources would not be expended. At this cut-off, only 43% of all patients who might have undergone CEEG would be selected to undergo CEEG. Given a seizure prevalence of 30%, this would result in a PPV of 47% and NPV of 91%. In contrast, a center with more limited CEEG resources might only perform CEEG for any patient with a model score >0.45. At this cut-off, 81% of patients with ES would not undergo CEEG so the seizures would not be identified and managed. However, 97% of patients without ES would be identified as not needing CEEG, so limited CEEG resources would not be expended. Given a seizure prevalence of 30%, this would result in a PPV of 74% and NPV of 74%.
There are limitations to these data. First, the model included a limited number of categorized variables. While this kept the model simple and focused on data readily available to clinicians at admission, utilizing additional clinical and EEG variables might yield better predictive models. For example, etiology was categorized as structural or non-structural, and future larger studies using more exact etiologic categories might yield better predictive models. Additionally, a limited number of clinical variables were included, and future studies might include variables related to critical illness severity, neuroimaging, hypoxia, hypotension, vasopressor use, and markers of injury to other organs. Second, the multi-center dataset used for Table 4 Using the logistic regression formula or the pre-calculated resulting model scores for each combination of variables shown in Table 3 a patient's model score would be identified. Patients with model scores above an institutionally determined model score cut-off would undergo CEEG. For various cut-offs the sensitivity and specificity are provided for the creation and validation datasets. Compared to all patients who underwent CEEG in the datasets, the percentage of patients who would be above the model score cutoff and thus undergo CEEG are provided for each cutoff. Bold font indicates the model score cut-off maximizing sensitivity and specificity. Developing a model which is well calibrated across diverse settings is difficult since models with a limited number of predictors always leave some variance between subjects unexplained. The intercept from the validation plot was greater than zero and the fitted line between observed seizure frequencies and predicted frequencies was above the 458 diagonal line indicating the model under-predicted seizures on average in the validation dataset. Seizure occurrence was significantly higher in the validation than creation dataset, whereas three out of four predictor variables were distributed similarly between the two datasets. A model developed from a low outcome rate population applied to a higher outcome rate population will produce underprediction. These data suggest we should aim to identify and include additional predictive variables. Fourth, the model requires information obtained from a routine EEG (EEG background category and inter-ictal epileptiform discharge category) so implementation still requires EEG technologist work. However, selecting patients who need only routine EEGs and not CEEG may still be useful by reducing technologist work time at bedside (electrode placement may be quicker for many patients since electrodes could be applied with paste rather than collodion), physician work time (fewer patients undergoing CEEG would reduce the pages of EEG to be reviewed each day) and equipment needs (collector equipment would not need to remain at bedside for CEEG). Fifth, ES occurrence and background category were determined by a number of encephalographers from each site for the multi-center dataset and one encephalographer for the single center dataset. Further, the multi-center data was obtained by chart review of CEEG reports and not be re-review of the CEEG tracings. There were likely some inter-rater differences in EEG interpretation. 27 Multi-rater scoring using unified seizure definitions 34, 35 may improve model performance.
We created the prediction model using multi-center data and validated it using single center data. Studying ES epidemiology and impact on outcome will likely require multi-center studies to enroll sufficient patients, particularly if patients are to be stratified by injury type. Consortia are already performing initial multicenter studies working toward these goals. 13, 24, 25 Our field will need to determine whether these multi-center data can be applied meaningfully at individual institutions despite inherent interinstitutional variability. These considerations guided our decision to develop the model using multi-center data and validate it using single center data, rather than vice versa. The fact that the model had predictive ability indicates that future studies using larger multi-center datasets incorporating more variables could have meaningful applicability when applied at individual centers. We are working to develop a free app which could easily calculate model scores when predictor variables are entered (Supplementary Fig. 2 ). Development of this type of tool could make complex predictor models developed over time easily implementable by clinicians.
Conclusions
The current model was based on small number of clinically known variables, was developed in a broad cohort of patients who underwent clinically indicated CEEG at 11 institutions and was validated in a broad cohort of patients at a single center. Despite these limitations, the model had fair to good discrimination ability and may help clinicians consider multiple risk factors together when making decisions regarding CEEG use. With further development including more defined subject cohorts and additional predictor variables, these data suggest that prediction models derived from multi-center data could yield improved CEEG efficiency at individual centers.
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